{"id":92274,"date":"2019-06-18T06:22:54","date_gmt":"2019-06-18T13:22:54","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/06\/unity-biotechnology-reports-promising-topline-data-from-phase-1-first-in-human-study-of-ubx0101-in-patients-with-osteoarthritis-of-the-knee"},"modified":"2019-06-18T06:22:54","modified_gmt":"2019-06-18T13:22:54","slug":"unity-biotechnology-reports-promising-topline-data-from-phase-1-first-in-human-study-of-ubx0101-in-patients-with-osteoarthritis-of-the-knee","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/06\/unity-biotechnology-reports-promising-topline-data-from-phase-1-first-in-human-study-of-ubx0101-in-patients-with-osteoarthritis-of-the-knee","title":{"rendered":"UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/logo.unity-biotechnology-reports-promising-topline-data-from-phase-1-first-in-human-study-of-ubx0101-in-patients-with-osteoarthritis-of-the-knee2.jpg\"><\/a><\/p>\n<p>It\u2019s a start. So far so good, senolytics.<\/p>\n<hr>\n<p>SAN FRANCISCO, June 18, 2019 (GLOBE NEWSWIRE) \u2014 UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced promising results from its first-in-human Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee. The study demonstrated that UBX0101 was safe and well-tolerated. Improvement in several clinical measures, including pain, function, as well as modulation of certain senescence-associated secretory phenotype (SASP) factors and disease-related biomarkers was observed after a single dose of UBX0101.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>It\u2019s a start. So far so good, senolytics. SAN FRANCISCO, June 18, 2019 (GLOBE NEWSWIRE) \u2014 UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced promising results from its first-in-human Phase 1 study of UBX0101 in patients with moderate to [\u2026]<\/p>\n","protected":false},"author":388,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-92274","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/92274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/388"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=92274"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/92274\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=92274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=92274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=92274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}